Key result
Network meta-analyses using Bayesian principles are increasingly conducted to evaluate and rank cardiovascular disease treatments when direct clinical trial comparisons are lacking.
Answers are grounded in this paper and cite their sources.
Discusses the methodological principles and utility of network meta-analyses and SUCRA rankings in evaluating cardiovascular disease treatments.
The number of clinical trials registered has increased dramatically over the past two decades.1 Most of these studies are designed to compare a treatment with placebo, treatment as usual, or no treatment. As a result, clinical trials that provide direct comparisons among two or more effective treatments are lacking despite the possibility that such comparisons could readily inform clinical practice. To address this limitation, network meta-analyses are now being routinely conducted to evaluate all treatments simultaneously and generate pooled estimates for all comparisons, even when few or no such comparisons exist in the literature. The analysis of these networks frequently relies on Bayesian principles to estimate measures of association (e.g. the odds ratio (OR)) along with their associated interval estimates. These interval estimates are denoted as credible intervals (CrIs), instead of the more frequently encountered confidence intervals, to reflect the way Bayesian estimates are derived from the distribution of plausible (or credible) values generated by the model.2
No takes yet. Share an insight, caveat, or question.
Wang et al. (2018) conducted an editorial in cardiovascular disease. Network meta-analyses using Bayesian principles are increasingly conducted to evaluate and rank cardiovascular disease treatments when direct clinical trial comparisons are lacking.
Synapse has enriched 10 related papers. Consider them for comparative context: